Page 5 - Five Prime News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021 LUMAKRAS™ (Sotorasib)¹ Overall Survival and Biomarker Subgroup Analyses From Registrational Phase 2 CodeBreaK 100 Trial in KRAS G12C-Mutated Non-Small Cell Lung Cancer New Data From the Phase 2 FIGHT Trial with Bemarituzumab in Advanced Gastric and Gastroesophageal Junction Cancers News provided by Share this article Share this article THOUSAND OAKS, Calif., May 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that new data from its expanding oncology pipeline and marketed portfolio will be presented during the 20...

Amgen Inc (AMGN) Q1 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Amgen Inc (NASDAQ: AMGN) Operator My name is Erica, and I will be your conference facilitator today for Amgen's First Quarter 2021 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.SPONSORED: 10 stocks we like better than Amgen When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, ...

Amgen today announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treatment for patients with fibroblast growth factor receptor 2b overexpressing and human epidermal growth factor receptor 2 -negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma in combination with modified FOLFOX6 based on … – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as first-line treat...

Breakthrough designation granted for Amgen’s bemarituzumab 20th April 2021 Amgen’s investigational medicine bemarituzumab has received a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA). The FDA has granted bemarituzumab a BTD for the first-line treatment of patients with fibroblast growth factor receptor 2b (FGFR2b) overexpressing and human epidermal growth factor receptor 2 (HER2)-negative metastatic and locally advanced gastric and gastroesophageal (GEJ) cancer. The BTD has been granted for bemarituzumab as a treatment for these patients when used i...

socaltech.com Thousand Oaks-based Amgen said this morning that it has successfully completed its $1.9 billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics. Five Prime's programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.